诺安基金唐晨：AI+生物医药爆发期将至

Core Viewpoint - The 2025 World Artificial Intelligence Conference (WAIC) in Shanghai highlighted the significant role of AI in accelerating drug development and transforming the healthcare ecosystem, with a focus on innovation in the pharmaceutical industry [1][4]. Industry Insights - AI technology is rapidly evolving, enabling faster analysis of vast medical data, predicting drug efficacy, and shortening drug development cycles while reducing costs [1][4]. - The global pharmaceutical landscape is undergoing a transformation, with multinational companies increasingly sourcing innovative drugs from China, driven by supportive domestic policies and steady clinical advancements [1][4]. - The innovative drug sector has shown strong performance, with the Wind Innovation Drug Index rising by 48.51% and the Hong Kong Innovation Drug Index increasing by 104.51% as of July 31, 2025 [3]. Company Performance - The performance of the Noan Selected Value Mixed Fund has been notable, with a net value growth rate of 61.88% over the past six months, significantly outperforming its benchmark of 5.74% [3]. - The fund's strategy has focused on the undervaluation of the pharmaceutical sector, with a balanced investment approach in both Hong Kong and A-share markets [3][4]. - The establishment of the "Technology Group" by Noan Fund in 2020 reflects a proactive approach to building a diverse product matrix in the technology investment space [4]. Technological Advancements - Modern surgical robots are enhancing surgical precision by analyzing real-time data and providing feedback, which reduces risks and improves success rates [2]. - The rise of remote surgery, facilitated by 5G/6G networks, allows surgeons to operate on patients from thousands of kilometers away, improving access to healthcare in remote areas [2].